The plasma fractionation market involves the collection and separation of human plasma into its key therapeutic components—such as immunoglobulins, clotting factors, albumin, and other plasma-derived proteins—used to treat conditions like immune deficiencies, hemophilia, liver disorders, and certain neurological diseases. Market growth is fueled by the rising prevalence of rare and chronic diseases, increasing use of immunoglobulins for autoimmune and inflammatory disorders, and growing demand for albumin in critical care and surgical applications. Advancements in fractionation technology, improved plasma collection methods, and expanding healthcare access in emerging economies also support market expansion. North America and Europe currently dominate due to well-established plasma collection networks and strong regulatory oversight, while Asia-Pacific is experiencing rapid growth driven by large patient populations and increasing government support for plasma-derived therapies. Key challenges include the high cost and complexity of plasma collection and processing, stringent regulatory requirements, and the ongoing need to ensure a safe, reliable plasma supply
The global plasma fractionation market size was valued at USD 37.31 billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a CAGR of 8.75% during the forecast period. North America dominated the plasma fractionation market with a 56.18% share in 2024, supported by advanced healthcare infrastructure, high demand for immunoglobulins and coagulation factors, and strong presence of leading biopharmaceutical companies in the region.
In July 2024, Kedrion S.p.A. disclosed a major step forward by establishing the framework for a long-term agreement with Biotest AG to fully commercialize and distribute the immunoglobulin therapy Yimmugo in the U.S. market. This alliance reflects the growing strategic emphasis on immunoglobulin therapies and underscores how collaborations are shaping the competitive landscape.